Friday, October 2, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document

Untitled source document

No live link available for this source.

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Meta intends to deepen engagement with U.S. government, military, and industry stakeholders urgently seeking domestic sources of critical minerals

    60% confidence
  • Zircon, titanium, rare earth elements, scandium, and vanadium are U.S.-designated critical minerals with applications in aerospace & defence, nuclear energy, and advanced manufacturing where domestic sourcing is a stated national security priority

    60% confidence
  • Meta is actively engaging with Canadian federal and provincial governments to advance Table Mountain toward permitting and production, with potential government participation forming a key financing component

    60% confidence
  • Tsagaan Zalaa securing offtake agreements could mark the Company's transition from developer to operator with its first cash-flowing asset

    60% confidence
  • Tsagaan Zalaa is the first step in building an operating platform that management intends to grow across its broader portfolio of development-stage assets

    60% confidence
  • Table Mountain is one of Canada's most strategically positioned silica projects

    60% confidence
  • The Company is well-capitalized with no debt following the $6.5 million financing close

    60% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI-Driven Drug Development Meets Biotech Deal-Making and Regulatory Catalysts
AI-designed therapeutics (Insilico's rentosertib showing biological-age reductions) are moving into the clinical mainstream. Large-cap biotech is simultaneously reallocating capital through M&A (Lilly–Merida, $2.9B) and government funding (BARDA–Basilea), while trial failures (ziltivekimab, a 9.4% Novo Nordisk share drop) and upcoming FDA catalysts (the ivonescimab PDUFA on 2026-11-14) drive volatility. The wider AI regulatory and legal climate (Tesla Cybercab probe, xAI's Minnesota loss, OpenAI suits) is tightening, though QAIAx's micro-cap trial claims are speculative and weakly connected.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,327 source documents archived
Query this data → isubstrate.com